<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39318909</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Genetic Polymorphisms of Angiotensin-Converting Enzyme 1 (ACE1) and ACE2 Associated With Severe Acute Respiratory Syndrome COVID-19 in the Palestinian Population.</ArticleTitle><Pagination><StartPage>e67670</StartPage><MedlinePgn>e67670</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e67670</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.67670</ELocationID><Abstract><AbstractText>As a key enzyme of the renin-angiotensin system (RAS), angiotensin-converting enzyme 2 (ACE2) is a validated receptor for SARS-CoV-2, linking RAS to COVID-19. Functional ACE1/ACE2 gene polymorphisms likely cause an imbalance in the ACE1/ACE2 ratio, triggering RAS imbalance and may contribute to COVID-19 complications. This study aimed to investigate four single nucleotide polymorphisms (SNPs) of ACE1 and ACE2 genes, three for ACE1 (rs4343, rs4342, rs4341) and one for ACE2 (rs2285666), in patients with COVID-19 among the Palestinian population. A total of 130 blood samples were collected, including 50 negative controls without COVID-19 infection, 50 cases with COVID-19 infection but not hospitalized, and 30 patients with severe COVID-19 infection hospitalized in the intensive care unit. Fragments of the ACE1 and ACE2 genes, including the targeted SNPs, were amplified using multiplex PCR and subsequently genotyped by next-generation sequencing with specific virtual probes. Our results revealed that ACE2 rs2285666 GG genotype carriers were more prevalent in COVID-19 patients compared to the control group (P=0.049), while no statistical differences were observed in the distribution of ACE1 (rs4343, rs4342, rs4341) variants between COVID-19 patients and the control group. GA carriers of ACE2, rs2285666, among cases and ICU groups were at lower risk of getting COVID-19 infection (P=0.002 and P=0.013, respectively), and they were unlikely to develop fatigue (P=0.043), headache (P=0.007), loss of smell (P=0.028), and dyspnea (P=0.005). Age and comorbidities such as hypertension and coronary artery disease (CAD) were independent risk factors for COVID-19 disease. Symptoms of COVID-19 patients such as fatigue, headaches, runny noses, and loss of smell were significantly higher in non-hospitalized cases of COVID-19, while dyspnea was more frequent in the ICU patients. In conclusion, these findings indicate that the ACE2 rs2285666 GG genotype is associated with an increased risk of COVID-19 infection. This association suggests a potential genetic predisposition linked to the ACE2 gene, which may influence the susceptibility and severity of the disease.</AbstractText><CopyrightInformation>Copyright © 2024, AbuSaleh et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>AbuSaleh</LastName><ForeName>Lama</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Biochemistry and Molecular Biology Department, Faculty of Medicine, Al-Quds University, Jerusalem, PSE.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ereqat</LastName><ForeName>Suheir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biochemistry and Molecular Biology Department, Al-Quds University, Jerusalem, PSE.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Jawabreh</LastName><ForeName>Amer</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Laboratory Sciences Department, Faculty of Allied Health Sciences, Arab American University, Jerusalem, PSE.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasereddin</LastName><ForeName>Abedelmajeed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious Disease Department, Al-Quds University, Al-Quds Bard College, Jerusalem, PSE.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ace1</Keyword><Keyword MajorTopicYN="N">angiotensin-converting enzyme 2 (ace2)</Keyword><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">genetic analysis</Keyword><Keyword MajorTopicYN="N">next-generation sequencing (ngs)</Keyword><Keyword MajorTopicYN="N">ras (renin angiotensin system)</Keyword><Keyword MajorTopicYN="N">severity of disease</Keyword></KeywordList><CoiStatement>Human subjects: Consent was obtained or waived by all participants in this study. Research Ethics Committee at Al-Quds University issued approval (184/REC/2021). The study procedure was approved by the research ethics committee at Al-Quds University (184/REC/2021). Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>4</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39318909</ArticleId><ArticleId IdType="pmc">PMC11420599</ArticleId><ArticleId IdType="doi">10.7759/cureus.67670</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weekly epidemiological update on COVID-19.  [
Aug;
2024 
];https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2023 2023 19:13–2023.</Citation></Reference><Reference><Citation>Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection. Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, et al. Clin Microbiol Rev. 2021;34:0–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8142517</ArticleId><ArticleId IdType="pubmed">33980687</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Chen N, Zhou M, Dong X, et al. Lancet. 2020;395:507–513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Kai H, Kai M. Hypertens Res. 2020;43:648–654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184165</ArticleId><ArticleId IdType="pubmed">32341442</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiotensin-(1-7) promotes resolution of eosinophilic inflammation in an experimental model of asthma. Magalhaes GS, Barroso LC, Reis AC, et al. Front Immunol. 2018;9:58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5797293</ArticleId><ArticleId IdType="pubmed">29434591</ArticleId></ArticleIdList></Reference><Reference><Citation>ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Hashimoto T, Perlot T, Rehman A, et al. Nature. 2012;487:477–481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095315</ArticleId><ArticleId IdType="pubmed">22837003</ArticleId></ArticleIdList></Reference><Reference><Citation>Going viral in the islet: mediators of SARS-CoV-2 entry beyond ACE2. Rangu R, Wander PL, Barrow BM, Zraika S. J Mol Endocrinol. 2022;69:0–79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10622140</ArticleId><ArticleId IdType="pubmed">35521990</ArticleId></ArticleIdList></Reference><Reference><Citation>Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Matsuyama S, Ujike M, Morikawa S, Tashiro M, Taguchi F. Proc Natl Acad Sci U S A. 2005;102:12543–12547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1194915</ArticleId><ArticleId IdType="pubmed">16116101</ArticleId></ArticleIdList></Reference><Reference><Citation>Targeting TMPRSS2 and cathepsin B/L together may be synergistic against SARS-CoV-2 infection. Padmanabhan P, Desikan R, Dixit NM. PLoS Comput Biol. 2020;16:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7748278</ArticleId><ArticleId IdType="pubmed">33290397</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Liu Y, Yang Y, Zhang C, et al. Sci China Life Sci. 2020;63:364–374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7088566</ArticleId><ArticleId IdType="pubmed">32048163</ArticleId></ArticleIdList></Reference><Reference><Citation>Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. Liu Z, Xiao X, Wei X, et al. J Med Virol. 2020;92:595–601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228221</ArticleId><ArticleId IdType="pubmed">32100877</ArticleId></ArticleIdList></Reference><Reference><Citation>Responses of serum and lung angiotensin-converting enzyme activities in the early phase of pulmonary damage induced by oleic acid in dogs. Nukiwa T, Matsuoka R, Takagi H, Ishii Y, Arai T, Kira S. Am Rev Respir Dis. 1982;126:1080–1086.</Citation><ArticleIdList><ArticleId IdType="pubmed">6295220</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. J Hum Hypertens. 2007;21:20–27.</Citation><ArticleIdList><ArticleId IdType="pubmed">17096009</ArticleId></ArticleIdList></Reference><Reference><Citation>The role of angiotensin-converting enzyme 2 (ACE2) genetic variations in COVID-19 infection: a literature review. Fawzy MS, Ashour H, Shafie AA, et al. Egypt J Med Hum Genet. 2022;23:97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9142348</ArticleId><ArticleId IdType="pubmed">37521836</ArticleId></ArticleIdList></Reference><Reference><Citation>ACE2 polymorphisms as potential players in COVID-19 outcome. Khayat AS, de Assumpção PP, Meireles Khayat BC, et al. PLoS One. 2020;15:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7769452</ArticleId><ArticleId IdType="pubmed">33370311</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease. Sabater Molina M, Nicolás Rocamora E, Bendicho AI, et al. PLoS One. 2022;17:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8815985</ArticleId><ArticleId IdType="pubmed">35120165</ArticleId></ArticleIdList></Reference><Reference><Citation>Genetic association of ACE2 rs2285666 polymorphism with COVID-19 spatial distribution in India. Srivastava A, Bandopadhyay A, Das D, et al. Front Genet. 2020;11:564741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7545580</ArticleId><ArticleId IdType="pubmed">33101387</ArticleId></ArticleIdList></Reference><Reference><Citation>SNPs of ACE1 (rs4343) and ACE2 (rs2285666) genes are linked to SARS-CoV-2 infection but not with the severity of disease. Alimoradi N, Sharqi M, Firouzabadi D, Sadeghi MM, Moezzi MI, Firouzabadi N. Virol J. 2022;19:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8934128</ArticleId><ArticleId IdType="pubmed">35305693</ArticleId></ArticleIdList></Reference><Reference><Citation>Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in Caucasians with type 2 diabetes. Patel SK, Wai B, Ord M, et al. Am J Hypertens. 2012;25:216–222.</Citation><ArticleIdList><ArticleId IdType="pubmed">21993363</ArticleId></ArticleIdList></Reference><Reference><Citation>Interaction of A-240T and A2350G related genotypes of angiotensin-converting enzyme (ACE) is associated with decreased serum ACE activity and blood pressure in a healthy Iranian population. Firouzabadi N, Tajik N, Shafiei M, Ebrahimi SA, Bakhshandeh H. Eur J Pharmacol. 2011;668:241–247.</Citation><ArticleIdList><ArticleId IdType="pubmed">21810419</ArticleId></ArticleIdList></Reference><Reference><Citation>Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Leisman DE, Deutschman CS, Legrand M. Intensive Care Med. 2020;46:1105–1108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186535</ArticleId><ArticleId IdType="pubmed">32347323</ArticleId></ArticleIdList></Reference><Reference><Citation>Innate immunity in children and the role of ACE2 expression in SARS-CoV-2 infection. Dioguardi M, Cazzolla AP, Arena C, et al. Pediatr Rep. 2021;13:363–382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8293341</ArticleId><ArticleId IdType="pubmed">34287338</ArticleId></ArticleIdList></Reference><Reference><Citation>Association of IFNAR2 rS2236757 and OAS3 rS10735079 polymorphisms with susceptibility to COVID-19 infection and severity in Palestine. Abdelhafez M, Nasereddin A, Shamma OA, et al. Interdiscip Perspect Infect Dis. 2023;2023:9551163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10517872</ArticleId><ArticleId IdType="pubmed">37745867</ArticleId></ArticleIdList></Reference><Reference><Citation>Classical and alternative receptors for SARS-CoV-2 therapeutic strategy. Masre SF, Jufri NF, Ibrahim FW, Abdul Raub SH. Rev Med Virol. 2021;31:1–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883063</ArticleId><ArticleId IdType="pubmed">33368788</ArticleId></ArticleIdList></Reference><Reference><Citation>The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Verdecchia P, Cavallini C, Spanevello A, Angeli F. Eur J Intern Med. 2020;76:14–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167588</ArticleId><ArticleId IdType="pubmed">32336612</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome. Gómez J, Albaiceta GM, García-Clemente M, et al. Gene. 2020;762:145102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456966</ArticleId><ArticleId IdType="pubmed">32882331</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk of hospitalization and mortality due to COVID-19 in people with obesity: an analysis of data from a Brazilian state. Reis EC, Rodrigues P, Jesus TR, de Freitas Monteiro EL, Virtuoso Junior JS, Bianchi L. PLoS One. 2022;17:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8896734</ArticleId><ArticleId IdType="pubmed">35245299</ArticleId></ArticleIdList></Reference><Reference><Citation>The lung, the heart, the novel coronavirus, and the renin-angiotensin system; the need for clinical trials. Lumbers ER, Delforce SJ, Pringle KG, Smith GR. Front Med (Lausanne) 2020;7:248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7256451</ArticleId><ArticleId IdType="pubmed">32574336</ArticleId></ArticleIdList></Reference><Reference><Citation>Genetic variability in the expression of the SARS-CoV-2 host cell entry factors across populations. Ortiz-Fernández L, Sawalha AH. Genes Immun. 2020;21:269–272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484169</ArticleId><ArticleId IdType="pubmed">32759995</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>